27838407|t|Pentraxin 3 in neonates with and without diagnosis of pulmonary hypertension
27838407|a|Pentraxin 3 is a novel biomarker produced by vascular endothelial cells and macrophages. In recent studies involving adults, pentraxin 3 has been introduced as a reliable biomarker in the evaluation of cardiovascular disease and pulmonary hypertension. This study was conducted with an aim to measure the level of pentraxin 3 in neonates with pulmonary hypertension and comparing with normal healthy controls. In a case-control study, plasma pentraxin 3 levels were evaluated in 3 groups of neonates including neonates with pulmonary arterial hypertension (PAH), neonates with congenital heart disease without pulmonary arterial hypertension (CHD-PAH) and normal healthy neonates. Plasma pentraxin 3 levels in 72 neonates (21 in PAH, 19 in CHD-PAH, and 32 in control group) were measured. Demographic characteristics had no significant statistical difference among the 3 groups. Pentraxin 3 levels in PAH group was significantly higher than CHD-PAH and control groups (2.12±2.32 vs. 0.58±0.57 and 1.03±1.38ng/mL, P=0.008, respectively). No significant correlation was found between concentrations of pentraxin 3 and cardiac ejection fractions between PAH and CHD-PAH (r=0.009, P=0.97). However, significant positive correlation was detected between PTX3 concentrations and pulmonary pressures between these two groups (r=0.499, P=0.001). Results from our study showed that pentraxin 3 levels were increased in newborn infants with pulmonary hypertension. Plasma pentraxin 3 could be considered as a novel adjunct diagnostic tool in the evaluation of pulmonary hypertension in combination with echocardiography or as a diagnostic tool when echocardiography is not readily available for confirmation of increased pulmonary pressure.
27838407	0	11	Pentraxin 3	T116,T123	C0174234
27838407	15	23	neonates	T100	C0021289
27838407	41	50	diagnosis	T062	C1704656
27838407	54	76	pulmonary hypertension	T046	C0020542
27838407	77	88	Pentraxin 3	T116,T123	C0174234
27838407	100	109	biomarker	T201	C0005516
27838407	122	148	vascular endothelial cells	T025	C1257792
27838407	153	164	macrophages	T025	C0024432
27838407	176	183	studies	T062	C2603343
27838407	194	200	adults	T100	C0001675
27838407	202	213	pentraxin 3	T116,T123	C0174234
27838407	248	257	biomarker	T201	C0005516
27838407	265	275	evaluation	T058	C0220825
27838407	279	301	cardiovascular disease	T047	C0007222
27838407	306	328	pulmonary hypertension	T046	C0020542
27838407	335	340	study	T062	C2603343
27838407	370	377	measure	T081	C0079809
27838407	382	387	level	T080	C0441889
27838407	391	402	pentraxin 3	T116,T123	C0174234
27838407	406	414	neonates	T100	C0021289
27838407	420	442	pulmonary hypertension	T046	C0020542
27838407	447	456	comparing	T052	C1707455
27838407	469	476	healthy	T080	C3898900
27838407	477	485	controls	T096	C0009932
27838407	492	510	case-control study	T062	C0007328
27838407	512	518	plasma	T031	C0032105
27838407	519	530	pentraxin 3	T116,T123	C0174234
27838407	531	537	levels	T080	C0441889
27838407	543	552	evaluated	T058	C0220825
27838407	558	564	groups	T098	C1257890
27838407	568	576	neonates	T100	C0021289
27838407	587	595	neonates	T100	C0021289
27838407	601	632	pulmonary arterial hypertension	T047	C2973725
27838407	634	637	PAH	T047	C2973725
27838407	640	648	neonates	T100	C0021289
27838407	654	678	congenital heart disease	T019	C0152021
27838407	679	686	without	T080	C0332288
27838407	687	718	pulmonary arterial hypertension	T047	C2973725
27838407	720	727	CHD-PAH	T019	C0152021
27838407	740	747	healthy	T080	C3898900
27838407	748	756	neonates	T100	C0021289
27838407	758	764	Plasma	T031	C0032105
27838407	765	776	pentraxin 3	T116,T123	C0174234
27838407	777	783	levels	T080	C0441889
27838407	790	798	neonates	T100	C0021289
27838407	806	809	PAH	T047	C2973725
27838407	817	824	CHD-PAH	T019	C0152021
27838407	836	849	control group	T096	C0009932
27838407	856	864	measured	T080	C0444706
27838407	866	893	Demographic characteristics	T078	C0011292
27838407	898	900	no	T033	C1513916
27838407	901	924	significant statistical	T081	C0237881
27838407	948	954	groups	T098	C1257890
27838407	956	967	Pentraxin 3	T116,T123	C0174234
27838407	968	974	levels	T080	C0441889
27838407	978	981	PAH	T047	C2973725
27838407	982	987	group	T098	C1257890
27838407	1006	1012	higher	T080	C0205250
27838407	1018	1025	CHD-PAH	T019	C0152021
27838407	1030	1044	control groups	T096	C0009932
27838407	1114	1116	No	T033	C1513916
27838407	1117	1140	significant correlation	T080	C1707520
27838407	1159	1173	concentrations	T081	C1446561
27838407	1177	1188	pentraxin 3	T116,T123	C0174234
27838407	1193	1219	cardiac ejection fractions	T042	C0232174
27838407	1228	1231	PAH	T047	C2973725
27838407	1236	1243	CHD-PAH	T019	C0152021
27838407	1284	1292	positive	T033	C1446409
27838407	1293	1304	correlation	T080	C1707520
27838407	1309	1317	detected	T033	C0442726
27838407	1326	1330	PTX3	T116,T123	C0174234
27838407	1331	1345	concentrations	T081	C1446561
27838407	1350	1369	pulmonary pressures	T060	C1168098
27838407	1388	1394	groups	T098	C1257890
27838407	1415	1422	Results	T169	C1274040
27838407	1432	1437	study	T062	C2603343
27838407	1450	1461	pentraxin 3	T116,T123	C0174234
27838407	1462	1468	levels	T080	C0441889
27838407	1474	1483	increased	T081	C0205217
27838407	1487	1502	newborn infants	T100	C0021289
27838407	1508	1530	pulmonary hypertension	T046	C0020542
27838407	1532	1538	Plasma	T031	C0032105
27838407	1539	1550	pentraxin 3	T116,T123	C0174234
27838407	1582	1605	adjunct diagnostic tool	T073	C0336791
27838407	1613	1623	evaluation	T058	C0220825
27838407	1627	1649	pulmonary hypertension	T046	C0020542
27838407	1670	1686	echocardiography	T060	C0013516
27838407	1695	1710	diagnostic tool	T073	C0336791
27838407	1716	1732	echocardiography	T060	C0013516
27838407	1778	1806	increased pulmonary pressure	T033	C0852853